30 patents
Utility
Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
13 Apr 23
The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
Filed: 24 May 22
Utility
Synthesis of Protected 3'-amino Nucleoside Monomers
23 Mar 23
Orthogonally protected 3′-amino nucleoside monomers and efficient methods for their synthesis are described.
Sergei M. Gryaznov, Krisztina Pongracz, Daria Zielinska
Filed: 25 May 22
Utility
Process for Preparing Imetelstat
9 Mar 23
Jale MUSLEHIDDINOGLU, Dinesh GALA, Jennifer Elizabeth ALBANEZE-WALKER
Filed: 12 Apr 22
Utility
Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1 -(protected hydroxy)-propane salts and methods of making the same
20 Dec 22
Aspects of the disclosure includes methods for preparing an amorphous solid composition of a fatty acid metal salt.
Jennifer E. Albaneze-Walker
Filed: 23 Oct 20
Utility
Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
13 Oct 22
The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
Filed: 23 Nov 21
Utility
Guanine Analogs as Telomerase Substrates and Telomere Length Affectors
29 Sep 22
This invention relates to compounds useful for inhibiting telomere elongation.
Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
Filed: 4 Mar 22
Utility
Oligonucleotide Compositions and Methods of Making the Same
29 Sep 22
The present disclosure provides a solid phase method of making oligonucleotides via sequential coupling cycles including at least one coupling of a dinucleotide dimer subunit to a free 3′-terminal group of a growing chain.
Premchandran H. Ramiya
Filed: 16 Mar 22
Utility
Methods of polynucleotide preparation using multivalent cation salt compositions
13 Sep 22
Aspects of the disclosure include methods for the preparation of a polynucleotide.
Premchandran H. Ramiya
Filed: 10 Jul 20
Utility
Combination Treatment for Hematological Cancers
2 Jun 22
The present invention relates to a combination treatment for hematological cancers.
Fei Huang, Joshua J. Rusbuldt, Aleksandra Rizo
Filed: 11 Feb 22
Utility
Subcutaneous Telomerase Inhibitor Compositions and Methods for Using Same
2 Jun 22
Aspects of the disclosure include telomerase inhibitor compositions formulated for subcutaneous administration.
Anil Kapur, Patrick Murphy
Filed: 15 Jul 21
Utility
Process for preparing imetelstat
17 May 22
Jale Muslehiddinoglu, Dinesh Gala, Jennifer Elizabeth Albaneze-Walker
Filed: 9 Jul 18
Utility
Combination treatment for hematological cancers
22 Mar 22
The present invention relates to a combination treatment for hematological cancers.
Fei Huang, Joshua J. Rusbuldt, Aleksandra Rizo
Filed: 28 Jul 17
Utility
Guanine analogs as telomerase substrates and telomere length affectors
22 Mar 22
This invention relates to compounds useful for inhibiting telomere elongation.
Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
Filed: 7 Feb 20
Utility
Use of a Janus Kinase Inhibitor and a Telomerase Inhibitor for the Treatment of Myeloproliferative Neoplasms
2 Sep 21
Aspects of the disclosure include methods for treating a myeloproliferative neoplasm.
Xiaoli Wang, Fei Huang
Filed: 3 Nov 20
Utility
Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
2 Sep 21
The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
Filed: 23 Sep 20
Utility
Crystalline Solids of 3-PALMITOYL-AMIDO-1,2-PROPANEDIOL and 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYLETHER-PROPANE and Methods of Making and Using the Same
20 May 21
Aspects of the disclosure include crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane.
Jennifer E. Albaneze-Walker
Filed: 23 Oct 20
Utility
Amorphous Solid Succinylated 3-(FATTY Acid AMIDO)-2-HYDROXY-1-(PROTECTED Hydroxy)-propane Salts and Methods of Making the Same
20 May 21
Aspects of the disclosure includes methods for preparing an amorphous solid composition of a fatty acid metal salt.
Jennifer E. Albaneze-Walker
Filed: 23 Oct 20
Utility
Synthesis of Protected 3'-Amino Nucleoside Monomers
2 Dec 20
Orthogonally protected 3′-amino nucleoside monomers and efficient methods for their synthesis are described.
Sergei M. Gryaznov, Krisztina Pongracz, Daria Zielinska
Filed: 30 Jul 20
Utility
Improved Process for Preparing Imetelstat
25 Nov 20
Jale MUSLEHIDDINOGLU, Dinesh GALA, Jennifer Elizabeth ALBANEZE-WALKER
Filed: 8 Jul 18
Utility
Methods of Polynucleotide Preparation Using Multivalent Cation Salt Compositions
28 Oct 20
Aspects of the disclosure include methods for the preparation of a polynucleotide.
Premchandran H. Ramiya
Filed: 9 Jul 20